B of A Securities Upgrades Bristol-Myers Squibb to Buy, Raises Price Target to $61

Benzinga · 2d ago
B of A Securities analyst Tim Anderson upgrades Bristol-Myers Squibb (NYSE:BMY) from Neutral to Buy and raises the price target from $52 to $61.